37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials

BACKGROUND: Immunocompromised (IC) populations are at increased risk of herpes zoster (HZ) and its related complications. RZV demonstrated > 68% efficacy against HZ in autologous hematopoietic stem cell transplant (HSCT) recipients ≥ 18 years of age (YOA). Here we present the safety data across 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Fauqued, Marta Lopez, Co, Maribel Miranda, Bastidas, Adriana, Beukelaers, Pierre, Dagnew, Alemnew F, Garcia, Juan Jose Fernandez, Schuind, Anne, da Silva, Fernanda Tavares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776055/
http://dx.doi.org/10.1093/ofid/ofaa439.082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776055/
http://dx.doi.org/10.1093/ofid/ofaa439.082

Ejemplares similares